WiseGuyReports.com adds “Pulmonary Fibrosis - Pipeline Review, H1 2016” new report to its research database. The report Spread across 380 pages with tables and figures.
The report “Pulmonary Fibrosis - Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.
Complete Report Details Available at https://www.wiseguyreports.com/reports/pulmonary-fibrosis-pipeline-review-h1-2016-fibrosis-pipeline-review-h1-2016 .
Companies mentioned in this report are:
AdAlta Pty Ltd., Advinus Therapeutics Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., AnaMar AB, Angion Biomedica Corp., Antitope Limited, aTyr Pharma, Inc., Biogen, Inc., Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celgene Corporation, Chong Kun Dang Pharmaceutical Corp., Clanotech AB, Compugen Ltd., Cynata Therapeutics Limited, Diffusion Pharmaceuticals Inc., Digna Biotech, S.L., Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Galapagos NV, Galectin Therapeutics, Inc., GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., HanAll Biopharma Co., Ltd., HEC Pharm Co., Ltd., Histocell S.L., Hydra Biosciences, Inc., iBio, Inc., Inventiva, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, KineMed, Inc., Kyorin Pharmaceutical Co., Ltd., Lpath, Inc., miRagen Therapeutics, Inc., Moerae Matrix, Inc., MorphoSys AG, NicOx S.A., Novartis AG, Pacific Therapeutics Ltd., Pharmaxis Limited, Pharmicell Co., Ltd., Pluristem Therapeutics Inc., Progenra, Inc., Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., RedHill Biopharma Ltd., Respira Therapeutics, Inc., Rhizen Pharmaceuticals S.A., Ribomic Inc., Saje Pharma, LLC, Sanofi, SciFluor Life Sciences, LLC, Symic Biomedical, Inc., TaiwanJ Pharmaceuticals Co., Ltd., Teva Pharmaceutical Industries Limited, Therabron Therapeutics, Inc., Vericel Corporation, Yuhan Corporation.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/pulmonary-fibrosis-pipeline-review-h1-2016-fibrosis-pipeline-review-h1-2016 .
- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
P: +44 208 133 9349
M: +1 646 845 9349